APTO vs. PMCB, AIM, SNTI, TVGN, ZIVO, BCLI, COEP, ONVO, CHRO, and BCDA
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include PharmaCyte Biotech (PMCB), AIM ImmunoTech (AIM), Senti Biosciences (SNTI), Tevogen Bio (TVGN), ZIVO Bioscience (ZIVO), Brainstorm Cell Therapeutics (BCLI), Coeptis Therapeutics (COEP), Organovo (ONVO), Chromocell Therapeutics (CHRO), and BioCardia (BCDA). These companies are all part of the "biological products, except diagnostic" industry.
Aptose Biosciences (NASDAQ:APTO) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
Aptose Biosciences has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500.
Aptose Biosciences presently has a consensus target price of $19.80, suggesting a potential upside of 1,509.76%. Given Aptose Biosciences' higher probable upside, equities research analysts plainly believe Aptose Biosciences is more favorable than PharmaCyte Biotech.
26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are held by institutional investors. 9.5% of Aptose Biosciences shares are held by company insiders. Comparatively, 7.3% of PharmaCyte Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Aptose Biosciences had 1 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 1 mentions for Aptose Biosciences and 0 mentions for PharmaCyte Biotech. Aptose Biosciences' average media sentiment score of 0.00 equaled PharmaCyte Biotech'saverage media sentiment score.
PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
PharmaCyte Biotech's return on equity of -9.69% beat Aptose Biosciences' return on equity.
Aptose Biosciences received 375 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users.
Summary
Aptose Biosciences beats PharmaCyte Biotech on 7 of the 12 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
